Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05497401 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Controlled Study to Evaluate the Efficacy of Allogeneic MesenCure for the Treatment of Patients With ARDS

StatusNot Yet Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Jun 2026 to Jun 2028
    • Start date: Jun 2024 to Apr 2026
    • Study completion date: Jul 2026 to Oct 2028
    v3
  2. Primary completion date: Dec 31, 2023 to Jun 2026v2 Show 4 more changesShow less
    • Start date: Oct 2022 to Jun 2024
    • Study completion date: Jul 2024 to Jul 2026
    • Eligibility criteria revised
    • Study title shortened, about 1 word
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The efficacy of the allogeneic cell-therapy product MesenCure in addition to standard of care will be evaluated in comparison to placebo control in 300 moderate to severe Covid patients
Trial Details
NCT Number NCT05497401
Lead Sponsor BonusBio Group Ltd
Conditions
(from sponsor)		 ARDS
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov